interesting thoughts by scooter rmcCabe Rec
Post# of 153875
(Total Views: 727)
Posted On: 06/23/2020 3:36:43 PM
interesting thoughts by scooter rmcCabe
Recent 8K Filing Sign Of Potential Buyout.
The 8K was amended to include "accelerated vesting." Accelerated vesting is used as an incentive for key personnel to accept buyouts because it allows them immediately benefit from the increased share price by having immediate access to the options awarded them.
Typically in a buyout the most redundant employees are let go. The two most redundant employees in any company after a buyout are the CEO and CFO of from the acquired company.
It so happens the 8K was amended to provide our CEO and CFO "accelerated vesting." I would take this as a clue that offers are becoming more serious.
Another interesting note is Nader as stated on numerous occasions that he would not sell the company for anything below 100 dollars a share.
Who Would Buy Us Out?
Gilead: To protect its dominance in HIV drug market. Save face after the failure of Remdsivir.
Johnson And Johnson: Does a fair trade in the HIV market, pursuing a COVID vaccine.
GlaxoSmithKline: Looking to edge out any one of it's top 10 competitors.
Bristol Meyers Squibb: In the COVID race. Pursues cancer treatment and would be interested in our TNBC and basket trial. HIV income stream for them would also be nice.
The PR gained from having "THE" COVID drug in a completely barren landscape during the equivalent of a bio tech "space race" is of great value in and of itself.
So fingers crossed for our patients, and for a potential offer to good to pass up.
Recent 8K Filing Sign Of Potential Buyout.
The 8K was amended to include "accelerated vesting." Accelerated vesting is used as an incentive for key personnel to accept buyouts because it allows them immediately benefit from the increased share price by having immediate access to the options awarded them.
Typically in a buyout the most redundant employees are let go. The two most redundant employees in any company after a buyout are the CEO and CFO of from the acquired company.
It so happens the 8K was amended to provide our CEO and CFO "accelerated vesting." I would take this as a clue that offers are becoming more serious.
Another interesting note is Nader as stated on numerous occasions that he would not sell the company for anything below 100 dollars a share.
Who Would Buy Us Out?
Gilead: To protect its dominance in HIV drug market. Save face after the failure of Remdsivir.
Johnson And Johnson: Does a fair trade in the HIV market, pursuing a COVID vaccine.
GlaxoSmithKline: Looking to edge out any one of it's top 10 competitors.
Bristol Meyers Squibb: In the COVID race. Pursues cancer treatment and would be interested in our TNBC and basket trial. HIV income stream for them would also be nice.
The PR gained from having "THE" COVID drug in a completely barren landscape during the equivalent of a bio tech "space race" is of great value in and of itself.
So fingers crossed for our patients, and for a potential offer to good to pass up.
(7)
(0)